



## AVITA MEDICAL, INC. (ASX:AVH)

### **Corrective Notice under section 708A(9)(c) of the Corporations Act 2001 (Cth)**

**Valencia, Calif., USA, 10 April 2024 and Melbourne, Australia, 11 April 2024:** On 8 April 2024 (United States) / 9 April 2024 (Australia), AVITA Medical, Inc. (**Company**) issued a cleansing notice (**Notice**) and an ASX Appendix 3G in respect of the issue of 1,700 fully paid shares of common stock in the Company (**Shares**) that were made on 1 April (United States) / 2 April 2024 (Australia).

The Shares were issued as a result of the exercise by a former U.S. based employee of 170,000 unquoted options (which entitled the shareholder to be issued common stock in the Company rather than ordinary shares on a consolidation ratio of 100:1 as set out in the Company's pre-quotations disclosure released to the market on 24 June 2020). The Shares have been quoted on NASDAQ and the Company expects that any trading in the Shares will occur on NASDAQ. However, any holder has the right at any time to convert any of the Shares into CHESS Depository Interests of the Company, which trade on ASX.

At the time of lodgement of the Notice, the Company was finalising its assessment as to whether revised revenue guidance should be given in respect of its first quarter revenue and also whether the previously announced full year revenue range could be reaffirmed.

The Board of Directors of the Company has determined on 10 April 2024 (United States) / 11 April 2024 (Australia) that revised revenue guidance should be announced in respect of its first quarter and it has today lodged an announcement with ASX and NASDAQ providing such revised guidance. As revised guidance has been given, the Company may arguably, at the time of issuing the Notice, have been in possession of information, being the ongoing assessment of its first quarter and projected full year revenue, which ASX Listing Rule 3.1A would have excluded from disclosure under ASX Listing Rule 3.1. That information may have constituted 'excluded information' required to be included in the Notice pursuant to section 708A(6)(e) of the *Corporations Act 2001 (Cth)*.

Accordingly, the Company issues this Corrective Notice pursuant to and in accordance with section 708A(9)(c) of the Corporations Act for the purpose of correcting the Notice, which may be defective.

The Notice otherwise complies with section 708A(6) of the Corporations Act.

Authorised for release by the Board of Directors of the Company.

###

#### **ABOUT THE AVITA MEDICAL, INC.**

AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the US Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, in the United States.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE-mark approval in Europe and has PMDA approval in Japan.

To learn more, visit [www.avitamedical.com](http://www.avitamedical.com).

### **Forward-Looking Statements**

*Statements in this notice may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as "anticipate," "expect," "intend," "could," "may," "will," "believe," "estimate," "look forward," "forecast," "goal," "target," "project," "continue," "outlook," "guidance," "future," and similar words or expressions, and the use of future dates. These statements are made as of the date of this notice, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the "Risk Factors" section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.*

### **Investor & Media Contact:**

Jessica Ekeberg

Phone +1-661-904-9269

[investor@avitamedical.com](mailto:investor@avitamedical.com)

[media@avitamedical.com](mailto:media@avitamedical.com)

###